Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: Role of myeloperoxidase

Cancer Research

Volumn 61, Issue 21, 2001, Pages 7777-7784

  Kagan, V E ^a   Kuzmenko, A I ^a   Tyurina, Y Y ^a   Shvedova, A A ^a   Matsura, T ^a   Yalowich, J C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ETOPOSIDE; GLUTATHIONE; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COMPLEX FORMATION; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; HEME SYNTHESIS; HUMAN; HUMAN CELL; LIPID OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BIOTRANSFORMATION; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; ELECTRON SPIN RESONANCE SPECTROSCOPY; ETOPOSIDE; FREE RADICALS; HL-60 CELLS; HUMANS; HYDROGEN PEROXIDE; LIPID PEROXIDATION; OXIDATION-REDUCTION; PEROXIDASE; PHENOLS; PHOSPHOLIPIDS; REACTIVE OXYGEN SPECIES;

EID: 0035502997     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Oxidative stress inhibits apoptosis in human lymphoma cells
2. Oxidative stress interferes with cancer chemotherapy: Inhibition of lymphoma cell apoptosis and phagocytosis
3. Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen
4. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation
5. Plasma antioxidant status after high-dose chemotherapy: A randomized trial of parenteral nutrition in bone marrow transplantation patients
6. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells
7. The clinical pharmacology of etoposide
8. Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: Protective versus damaging effects of phenolic antioxidants
9. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: Free radical/antioxidant approach
10. Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity
11. Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and γ-glutamylcysteine synthetase levels during etoposide-induced oxidative stress
12. Peroxidase-catalyzed metabolism of etoposide (VP-16-213) and covalent binding of reactive intermediates to cellular macromolecules
13. Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation
14. Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives: An ESR Study
15. Tyrosinase-induced free radical formation from VP-16-213: Relationship to cytotoxicity
16. Secondary leukemias induced by topoisomerase-targeted drugs
17. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells
18. Nitric oxide-dependent pro-oxidant and pro-apoptotic effect of metallothioneins in HL-60 cells challenged with cupric nitrilotriacetate
19. Sensitive and specific fluorescent probing of oxidative stress in different classes of membrane phospholipids in live cells using metabolically integrated cis-parinaric acid
20. Determination of lipid phosphorus in the nanomolar range
21. Characterization of an amsacrine-resistant line of human leukemia cells: Evidence for a drug-resistant form of topoisomerase II
22. 2 in model systems and in HL-60 cells
23. 2-induced apoptosis of HL-60 human leukemia cells
24. The effects of inhibition of heme synthesis on the intracellular localization of iron in rat reticulocytes
25. Ascorbate is the primary reductant of the phenoxyl radical of etoposide (VP-16) in the presence of thiols both in cell homogenates and in model systems
26. Myeloperoxidase-catalyzed phenoxyl radicals of vitamin E homologue, 2,2,5,7,8-pentamethyl-6-hydroxy-chromane, do not induce oxidative stress in live HL-60 cells
27. Etoposide: Four decades of development of a topoisomerase II inhibitor
28. Reduction of phenoxyl radicals of the antitumor agent etoposide (VP-16) by glutathione and protein sulthydryls in human leukemia cells: Implications for cytotoxicity
29. Activation of topoisomerase II-mediated excision of chromosomal DNA loops during oxidative stress
30. Inhibition of human DNA topoisomerase II by hydroquinone and p-benzoquinone, reactive metabolites of benzene
31. Combination chemotherapy with teniposide (VM-26) and carboplatin in small cell lung cancer
32. Molecular effects of topoisomerase II inhibitors in AML cell lines: Correlation of apoptosis with topoisomerase II activity but not with DNA damage
33. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells
34. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells
35. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia
36. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins
37. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer
38. Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress
39. Cell cycle-coupled variation in topoisomerase IIα mRNA is regulated by the 3′-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation